The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.
   Google Scholar
• Gatt ME, Izraeli S. Lymphoid leukemias. Clinical immunology. Amsterdam, Netherlands: Elsevier; 2019. p. 1049–1063. e1.
   Google Scholar
• Caligaris-Cappio F, Bertilaccio MT, Scielzo C, editors. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Seminars in cancer biology. Amsterdam, Netherlands: Elsevier; 2014. doi:10.1016/j.semcancer.2013.06.010
   Google Scholar
• Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287–6296. doi:10.1182/blood-2011-01-328484
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. doi:10.1056/NEJMoa1513257
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Wang M, Wey S, Zhang Y, et al. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal. 2009;11(9):2307–2316. doi:10.1089/ars.2009.2485
   PubMed Web of Science ®Google Scholar
• McConkey DJ. The integrated stress response and proteotoxicity in cancer therapy. Biochem Biophys Res Commun. 2017;482(3):450–453. doi:10.1016/j.bbrc.2016.11.047
   PubMed Web of Science ®Google Scholar
• Lee ASJM. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods. 2005;35(4):373–381. doi:10.1016/j.ymeth.2004.10.010
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Talekar MK, Lulla AR, et al. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle. 2018;17(4):468–478. doi:10.1080/15384101.2017.1403689
   PubMed Web of Science ®Google Scholar
• Allen JE, Krigsfeld G, Patel L, et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015;14(1):1–10.
   PubMedGoogle Scholar
• Cole A, Wang Z, Coyaud E, et al. Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2015;27(6):864–876. doi:10.1016/j.ccell.2015.05.004
   PubMed Web of Science ®Google Scholar
• Greer YE, Porat-Shliom N, Nagashima K, et al. ONC201 kills breast cancer cells in vitro by targeting mitochondria. Oncotarget. 2018;9(26):18454–18479. doi:10.18632/oncotarget.24862
   PubMedGoogle Scholar
• Graves PR, Aponte-Collazo LJ, Fennell EMJ, et al. Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues. ACS Chem Biol. 2019;14(5):1020–1029. doi:10.1021/acschembio.9b00222
   PubMed Web of Science ®Google Scholar
• Ishizawa J, Zarabi SF, Davis RE, et al. Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell. 2019;35(5):721–737. e9. doi:10.1016/j.ccell.2019.03.014
   PubMed Web of Science ®Google Scholar
• Wang S, Dougan DA. The direct molecular target for imipridone ONC201 is finally established. Cancer Cell. 2019;35(5):707–708. doi:10.1016/j.ccell.2019.04.010
   PubMed Web of Science ®Google Scholar
• Seo JH, Rivadeneira DB, Caino MC, et al. The mitochondrial Unfoldase-Peptidase complex ClpXP controls bioenergetics stress and metastasis. PLoS Biol. 2016;14(7):e1002507. doi:10.1371/journal.pbio.1002507
   PubMed Web of Science ®Google Scholar
• Fatima N, Shen Y, Crassini K, et al. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. eJHaem. 2021;2(1):81–93. doi:10.1002/jha2.160
   PubMedGoogle Scholar
• Shen Y, Crassini K, Fatima N, et al. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Adv. 2020;4(20):5093–5106. doi:10.1182/bloodadvances.2019001369
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute–working group 1996 guidelines. Blood. 2008;111(12):5446–5456. doi:10.1182/blood-2007-06-093906
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia. 2008;22(7):1456–1459. Jul doi:10.1038/sj.leu.2405092
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363(9403):105–111. doi:10.1016/S0140-6736(03)15260-9
   PubMed Web of Science ®Google Scholar
• Tracy I, Tapper W, Parker A, et al. Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities. Br J Haematol. 2017;178(5):824–826. doi:10.1111/bjh.14172
   PubMed Web of Science ®Google Scholar
• Hertlein E, Beckwith KA, Lozanski G, et al. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One. 2013;8(10):e76607. doi:10.1371/journal.pone.0076607
   PubMed Web of Science ®Google Scholar
• Aubrey BJ, Kelly GL, Kueh AJ, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10(8):1422–1432. doi:10.1016/j.celrep.2015.02.002
   PubMed Web of Science ®Google Scholar
• Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6(5):513–519. doi:10.1038/74994
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi:10.1016/0065-2571(84)90007-4
   PubMedGoogle Scholar
• Shen Y, Crassini K, Sandhu S, et al. Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. Leuk Lymphoma. 2019;60(7):1632–1643. Jul doi:10.1080/10428194.2018.1542148
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461–466. doi:10.1080/10428190290011921
   PubMed Web of Science ®Google Scholar
• Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood J Am Soc Hematol. 1999;94(11):3658–3667.
   Google Scholar
• Kriston C, Plander M, Márk Á, et al. In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment. Ann Hematol. 2018;97(11):2145–2152. doi:10.1007/s00277-018-3410-x
   PubMed Web of Science ®Google Scholar
• Kline CLB, Ralff MD, Lulla AR, et al. Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia. 2018;20(1):80–91. doi:10.1016/j.neo.2017.10.002
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010–1014. doi:10.1126/science.1092734
   PubMed Web of Science ®Google Scholar
• Ishizawa J, Kojima K, Chachad D, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016;9(415):ra17–ra17.
   PubMed Web of Science ®Google Scholar
• Merendino AM, Bucchieri F, Campanella C, et al. Hsp60 is actively secreted by human tumor cells. PLoS One. 2010;5(2):e9247. doi:10.1371/journal.pone.0009247
   PubMed Web of Science ®Google Scholar
• Hsu HS, Lin JH, Huang WC, et al. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer. 2011;117(7):1516–1528. doi:10.1002/cncr.25599
   PubMed Web of Science ®Google Scholar
• Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526(7571):131–135. doi:10.1038/nature15260
   PubMed Web of Science ®Google Scholar
• Yun CW, Kim HJ, Lim JH, et al. Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells. 2019;9(1):60. doi:10.3390/cells9010060
   PubMed Web of Science ®Google Scholar
• Frezzato F, Raggi F, Martini V, et al. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. Int J Cancer. 2019;145(11):3089–3100. doi:10.1002/ijc.32383
   PubMed Web of Science ®Google Scholar
• Guo A, Lu P, Lee J, et al. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene. 2017;36(24):3441–3449. doi:10.1038/onc.2016.494
   PubMed Web of Science ®Google Scholar
• Hall L, Martinus RDJS. Hyperglycaemia and oxidative stress upregulate HSP60 & HSP70 expression in HeLa cells. SpringerPlus. 2013;2(1):1–10.
   PubMedGoogle Scholar
• Wu J, Liu T, Rios Z, et al. Heat shock proteins and cancer. Trends Pharmacol Sci. 2017;38(3):226–256. doi:10.1016/j.tips.2016.11.009
   PubMed Web of Science ®Google Scholar
• Deng P, Haynes CM, editors. Mitochondrial dysfunction in cancer: potential roles of ATF5 and the mitochondrial UPR. Seminars in cancer biology. Amsterdam, Netherlands: Elsevier; 2017. doi:10.1016/j.semcancer.2017.05.002
   Google Scholar
• Zhang Y, Huang Y, Yin Y, et al. ONC206, an imipridone derivative, induces cell death through activation of the integrated stress response in serous endometrial cancer in vitro. Front Oncol. 2020;10:2299.
   Web of Science ®Google Scholar
• Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89–102. doi:10.1038/nrm3270
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak PY, Tao W, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica 2022;107:58–76.
   Google Scholar
• Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649–657. doi:10.1038/leu.2013.358
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–2294. doi:10.1056/NEJMoa1400029
   PubMed Web of Science ®Google Scholar
• Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic ­lymphocytic leukemia. Anticancer Drugs. 2017;28(8):911–914. doi:10.1097/CAD.0000000000000522
   PubMed Web of Science ®Google Scholar